Yan Gong1, Zhongjie Fu1, Matthew L Edin1, Chi-Hsiu Liu1, Zhongxiao Wang1, Zhuo Shao1, Thomas W Fredrick1, Nicholas J Saba1, Peyton C Morss1, Samuel B Burnim1, Steven S Meng1, Fred B Lih1, Kin Sing Stephen Lee1, Elizabeth P Moran1, John Paul SanGiovanni1, Ann Hellström1, Bruce D Hammock1, Darryl C Zeldin1, Lois E H Smith2. 1. From the Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, MA (Y.G., Z.F., C.-H.L., Z.W., Z.S., T.W.F., N.J.S., P.C.M., S.B.B., S.S.M., E.P.M., L.E.H.S.); Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC (M.L.E., F.B.L., D.C.Z.); Department of Entomology and Comprehensive Cancer Center, University of California, Davis (K.S.S.L., B.D.H.); Section on Nutritional Neurosciences in the Laboratory of Membrane Biophysics and Biochemistry, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD (J.P.S.G.); and Department of Ophthalmology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden (A.H.). 2. From the Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, MA (Y.G., Z.F., C.-H.L., Z.W., Z.S., T.W.F., N.J.S., P.C.M., S.B.B., S.S.M., E.P.M., L.E.H.S.); Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC (M.L.E., F.B.L., D.C.Z.); Department of Entomology and Comprehensive Cancer Center, University of California, Davis (K.S.S.L., B.D.H.); Section on Nutritional Neurosciences in the Laboratory of Membrane Biophysics and Biochemistry, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD (J.P.S.G.); and Department of Ophthalmology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden (A.H.). lois.smith@childrens.harvard.edu.
Abstract
OBJECTIVE: Pathological ocular neovascularization is a major cause of blindness. Increased dietary intake of ω-3 long-chain polyunsaturated fatty acids (LCPUFA) reduces retinal neovascularization and choroidal neovascularization (CNV), but ω-3 LCPUFA metabolites of a major metabolizing pathway, cytochrome P450 oxidase (CYP) 2C, promote ocular pathological angiogenesis. We hypothesized that inhibition of CYP2C activity will add to the protective effects of ω-3 LCPUFA on neovascular eye diseases. APPROACH AND RESULTS: The mouse models of oxygen-induced retinopathy and laser-induced CNV were used to investigate pathological angiogenesis in the retina and choroid, respectively. The plasma levels of ω-3 LCPUFA metabolites of CYP2C were determined by mass spectroscopy. Aortic ring and choroidal explant sprouting assays were used to investigate the effects of CYP2C inhibition and ω-3 LCPUFA-derived CYP2C metabolic products on angiogenesis ex vivo. We found that inhibition of CYP2C activity by montelukast added to the protective effects of ω-3 LCPUFA on retinal neovascularization and CNV by 30% and 20%, respectively. In CYP2C8-overexpressing mice fed a ω-3 LCPUFA diet, montelukast suppressed retinal neovascularization and CNV by 36% and 39% and reduced the plasma levels of CYP2C8 products. Soluble epoxide hydrolase inhibition, which blocks breakdown and inactivation of CYP2C ω-3 LCPUFA-derived active metabolites, increased oxygen-induced retinopathy and CNV in vivo. Exposure to selected ω-3 LCPUFA metabolites of CYP2C significantly reversed the suppression of both angiogenesis ex vivo and endothelial cell functions in vitro by the CYP2C inhibitor montelukast. CONCLUSIONS: Inhibition of CYP2C activity adds to the protective effects of ω-3 LCPUFA on pathological retinal neovascularization and CNV.
OBJECTIVE: Pathological ocular neovascularization is a major cause of blindness. Increased dietary intake of ω-3 long-chain polyunsaturated fatty acids (LCPUFA) reduces retinal neovascularization and choroidal neovascularization (CNV), but ω-3 LCPUFA metabolites of a major metabolizing pathway, cytochrome P450 oxidase (CYP) 2C, promote ocular pathological angiogenesis. We hypothesized that inhibition of CYP2C activity will add to the protective effects of ω-3 LCPUFA on neovascular eye diseases. APPROACH AND RESULTS: The mouse models of oxygen-induced retinopathy and laser-induced CNV were used to investigate pathological angiogenesis in the retina and choroid, respectively. The plasma levels of ω-3 LCPUFA metabolites of CYP2C were determined by mass spectroscopy. Aortic ring and choroidal explant sprouting assays were used to investigate the effects of CYP2C inhibition and ω-3 LCPUFA-derived CYP2C metabolic products on angiogenesis ex vivo. We found that inhibition of CYP2C activity by montelukast added to the protective effects of ω-3 LCPUFA on retinal neovascularization and CNV by 30% and 20%, respectively. In CYP2C8-overexpressing mice fed a ω-3 LCPUFA diet, montelukast suppressed retinal neovascularization and CNV by 36% and 39% and reduced the plasma levels of CYP2C8 products. Soluble epoxide hydrolase inhibition, which blocks breakdown and inactivation of CYP2C ω-3 LCPUFA-derived active metabolites, increased oxygen-induced retinopathy and CNV in vivo. Exposure to selected ω-3 LCPUFA metabolites of CYP2C significantly reversed the suppression of both angiogenesis ex vivo and endothelial cell functions in vitro by the CYP2C inhibitor montelukast. CONCLUSIONS: Inhibition of CYP2C activity adds to the protective effects of ω-3 LCPUFA on pathological retinal neovascularization and CNV.
Authors: Andreas Stahl; Tim U Krohne; Przemyslaw Sapieha; Jing Chen; Ann Hellstrom; Emily Chew; Frank G Holz; Lois E H Smith Journal: Br J Ophthalmol Date: 2011-03-18 Impact factor: 4.638
Authors: A C Keech; P Mitchell; P A Summanen; J O'Day; T M E Davis; M S Moffitt; M-R Taskinen; R J Simes; D Tse; E Williamson; A Merrifield; L T Laatikainen; M C d'Emden; D C Crimet; R L O'Connell; P G Colman Journal: Lancet Date: 2007-11-07 Impact factor: 79.321
Authors: John Paul Sangiovanni; Elvira Agrón; A Dhananjayan Meleth; George F Reed; Robert D Sperduto; Traci E Clemons; Emily Y Chew Journal: Am J Clin Nutr Date: 2009-10-07 Impact factor: 7.045
Authors: Kip M Connor; John Paul SanGiovanni; Chatarina Lofqvist; Christopher M Aderman; Jing Chen; Akiko Higuchi; Song Hong; Elke A Pravda; Sharon Majchrzak; Deborah Carper; Ann Hellstrom; Jing X Kang; Emily Y Chew; Norman Salem; Charles N Serhan; Lois E H Smith Journal: Nat Med Date: 2007-06-24 Impact factor: 53.440
Authors: Yan Gong; Jie Li; Ye Sun; Zhongjie Fu; Chi-Hsiu Liu; Lucy Evans; Katherine Tian; Nicholas Saba; Thomas Fredrick; Peyton Morss; Jing Chen; Lois E H Smith Journal: PLoS One Date: 2015-07-10 Impact factor: 3.240
Authors: Yan Gong; Yohei Tomita; Matthew L Edin; Anli Ren; Minji Ko; Jay Yang; Edward Bull; Darryl C Zeldin; Ann Hellström; Zhongjie Fu; Lois E H Smith Journal: Metabolism Date: 2022-07-19 Impact factor: 13.934
Authors: Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2018-10 Impact factor: 8.311
Authors: Zhongjie Fu; Wenjun Yan; Chuck T Chen; Anders K Nilsson; Edward Bull; William Allen; Jay Yang; Minji Ko; John Paul SanGiovanni; James D Akula; Saswata Talukdar; Ann Hellström; Lois E H Smith Journal: Nutrients Date: 2022-03-23 Impact factor: 6.706
Authors: Yan Gong; Zhuo Shao; Zhongjie Fu; Matthew L Edin; Ye Sun; Raffael G Liegl; Zhongxiao Wang; Chi-Hsiu Liu; Samuel B Burnim; Steven S Meng; Fred B Lih; John Paul SanGiovanni; Darryl C Zeldin; Ann Hellström; Lois E H Smith Journal: EBioMedicine Date: 2016-09-30 Impact factor: 8.143
Authors: Zhongjie Fu; Raffael Liegl; Zhongxiao Wang; Yan Gong; Chi-Hsiu Liu; Ye Sun; Bertan Cakir; Samuel B Burnim; Steven S Meng; Chatarina Löfqvist; John Paul SanGiovanni; Ann Hellström; Lois E H Smith Journal: Invest Ophthalmol Vis Sci Date: 2017-08-01 Impact factor: 4.799